Sofosbuvir Off-label Treatment of Yellow Fever Patients During an Outbreak in Brazil, 2018: A Cohort Study

被引：3

作者：

Rezende, Izabela M. ^{[1
,2
,9
]}

Mendonca, Diogo Correa ^{[3
]}

Costa, Thais Alkifeles ^{[2
]}

de Oliveria, Gabriela Fernanda Garcia ^{[2
]}

Arruda, Matheus Soares ^{[2
]}

Goncalves, Andreza Parreiras ^{[4
]}

Alves, Pedro Augusto ^{[4
]}

Calzavara-Silva, Carlos Eduardo ^{[5
]}

Martins-Filho, Olindo A. ^{[6
]}

Teixeira-Carvalho, Andrea ^{[6
]}

Bonjardim, Claudio Antonio ^{[2
]}

Monath, Thomas P. ^{[7
]}

LaBeaud, A. Desiree ^{[1
]}

Drumond, Betania P. ^{[2
]}

Pascoal-Xavier, Marcelo Antonio

Pereira, Leonardo S. ^{[8
,10
]}

Ramalho, Dario Brock ^{[8
,11
]}

机构：

[1] Stanford Univ, Sch Med, Dept Pediat, Div Infect Dis, Stanford, CA USA

[2] Univ Fed Minas Gerais, Biol Sci Inst, Microbiol Dept, Lab Viruses, 6627 Antonio Carlos Ave Pampulha, BR-31270901 Belo Horizonte, MG, Brazil

[3] Univ Glasgow, Ctr Virus Res, MRC, Glasgow, Scotland

[4] Oswaldo Cruz Fdn Fiocruz, Rene Rachou Inst, Immunol Viral Dis, Belo Horizonte, MG, Brazil

[5] Oswaldo Cruz Fdn Fiocruz, Rene Rachou Inst, Cellular & Mol Immunol, Belo Horizonte, MG, Brazil

[6] Oswaldo Cruz Fdn Fiocruz, Rene Rachou Inst, Integrated Grp Biomarkers Res, Belo Horizonte, MG, Brazil

[7] Crozet Biopharm LLC, Lexington, MA USA

[8] Eduardo Menezes Hosp, Belo Horizonte, MG, Brazil

[9] Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Stanford Med Pandem Preparedness Hub, 240 Pasteur Dr Biomed Innovat Bldg BMI,3rd floor,R, Stanford, CA 94305 USA

[10] Bendigo Hlth, Bendigo, Vic, Australia

[11] Pan Amer Hlth Org, Brasilia, DF, Brazil

来源：

OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 06期

基金：

美国国家卫生研究院;

关键词：

antiviral; genomic viral load; sofosbuvir; yellow fever; yellow fever virus;

D O I：

10.1093/ofid/ofae312

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We enrolled 21 patients with laboratory-confirmed yellow fever (YF), hospitalized at Eduardo de Menezes Hospital, Brazil, to be treated with sofosbuvir, a drug approved for hepatitis C. Given the absence of specific YF antiviral treatments, the off-label nonrandomized sofosbuvir treatment aimed to address high disease severity and the risk of fatal outcomes. Patients received a daily dose of 400 mg sofosbuvir from 4 to 10 days post-symptom onset. YF viral load (VL) comparisons were made between treated and nontreated patients who either survived or died. The genomic VL for the treated group steadily decreased after day 7 post-symptom onset, suggesting that sofosbuvir might reduce YF VL. This study underscores the urgent need for YF antiviral therapies, advocating for randomized clinical trials to further explore sofosbuvir's role in YF treatment.

引用

页数：4

共 50 条

[31] Multiple drugsUrticarial vasculitis during off-label treatment: case report
Reactions Weekly, 2020, 1823 (1) : 255 - 255
[32] Off-Label Recombinant Factor VIIa Use in Pediatrics: a Multicenter Cohort Study
Witmer, Char
Lynch, Kevin G.
Raffini, Leslie
Shah, Samir S.
BLOOD, 2009, 114 (22) : 227 - 227
[33] Cohort study of new off-label gabapentin prescribing in chronic opioid users
Billig, Jessica, I
Bicket, Mark C.
Yazdanfar, Maryam
Gunaseelan, Vidhya
Sears, Erika D.
Brummett, Chad M.
Waljee, Jennifer F.
REGIONAL ANESTHESIA AND PAIN MEDICINE, 2024, 49 (02) : 88 - 93
[34] Treatment of Long-Haul COVID Patients With Off-Label Acyclovir
German, Emily R.
Jairath, Meera K.
Caston, John
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (04)
[35] Chikungunya Fever Outbreak in Brazil: Preliminary Assessment in a Cohort of Patients with Rheumatological Manifestations
Marques, Claudia
Cavalcanti, Nara
Luna, Mariana
Toche, Paula
Andrade, Carolina
Dantas, Andrea
Ranzolin, Aline
Rocha, Laurindo, Jr.
Freire, Eutilia
Cardoso, Pablo
Vilar, Kamila
Pereira, Michelly
Rego, Moacyr
Pitta, Maira
Duarte, Angela
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[36] BevacizumabProteinuria and arterial hypertension during off-label treatment: 2 case reports
Reactions Weekly, 2020, 1785 (1) : 110 - 110
[37] HydroxychloroquineBorderline prolongation of QTc interval during off-label treatment: case report
Reactions Weekly, 2020, 1829 (1) : 195 - 195
[38] Dramatic decline in a titi monkey population after the 2016-2018 sylvatic yellow fever outbreak in Brazil
Berthet, Melissa
Mesbahi, Geoffrey
Duvot, Guilhem
Zuberbuehler, Klaus
Casar, Cristiane
Bicca-Marques, Julio C.
AMERICAN JOURNAL OF PRIMATOLOGY, 2021, 83 (12)
[39] Haemagogus leucocelaenus and Haemagogus janthinomys are the primary vectors in the major yellow fever outbreak in Brazil, 2016-2018
Santos de Abreu, Filipe Vieira
Ribeiro, Ieda Pereira
Ferreira-de-Brito, Anielly
Cunha dos Santos, Alexandre Araujo
de Miranda, Rafaella Moraes
Bonelly, Iule de Souza
Sebastiao, Maycon
Neves, Alberto Santos
Bersot, Maria Ignez
dos Santos, Taissa Pereira
Gomes, Marcelo Quintela
da Silva, Jose Luis
Martins Romano, Alessandro Pecego
Carvalho, Roberta Gomes
do Carmo Said, Rodrigo Fabiano
Ribeiroi, Mario Sergio
Laperriere, Roberto da Costa
Lins Fonseca, Eduardo Oyama
Falqueto, Aloisio
Paupy, Christophe
Failloux, Anna-Bella
Moutailler, Sara
de Castro, Marcia Goncalves
Gomez, Mariela Martinez
Motta, Monique de Albuquerque
Bonaldo, Myrna Cristina
Lourenco-de-Oliveira, Ricardo
EMERGING MICROBES & INFECTIONS, 2019, 8 (01) : 218 - 231
[40] Off-label letrozole for tubal pregnancy monotherapy is not an alternative to methotrexate: a prospective cohort study
Gawron, Iwona M.
Babczyk, Dorota
Jach, Robert
GINEKOLOGIA POLSKA, 2025, 96 (01) : 51 - 57

← 1 2 3 4 5 →